Use of botulinum toxin therapy for prostatic hyperplasia and related disorders
View Patent ↗The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
1. A method for treating a prostatic disorder selected from the group consisting of prostatic hyperplasia, benign prostatic hyperplasia and prostatic enlargement in a patient, the method comprising the step of administering to the prostate of a patient with the prostatic disorder a botulinum toxin, thereby treating the prostatic disorder.
2. The method of claim 1 , wherein the patent is a human male.
3. The method of claim 1 , wherein the botulinum toxin is a botulinum toxin type A.
4. The method of claim 1 , wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, a powder, a cream, an emulsion, a suppository, a suspension, and a solution.
5. The method of claim 1 , wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation selected from the group consisting of a cream, a suspension and an emulsion.
6. The method of claim 1 , wherein the botulinum toxin is administered in an injectable, pharmaceutically acceptable formulation selected from the group consisting of a liquid, a cream, an emulsion, a suspension, and a solution.
7. The method of claim 1 , wherein the botulinum toxin is injected into the prostate gland of the patient in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, a cream, an emulsion, a suspension, and a solution.
8. The method of claim 1 , wherein the botulinum toxin is administered to the prostate of the patient by a route selected from the group consisting of a single unilateral injection, serial unilateral injections and bilateral injections.
9. The method of claim 1 , wherein the botulinum toxin is injected urethroscopically into the prostate of the patient.
10. The method of claim 1 , wherein the prostatic disorder is prostatic hyperplasia.
11. The method of claim 1 , wherein the prostatic disorder is benign prostatic hyperplasia.
12. The method of claim 1 , wherein the prostatic disorder is prostatic enlargement.
13. The method of claim 1 , wherein the prostatic disorder is secondary to abacterial prostatitis or prostarodynia.
14. The method of claim 1 , wherein administration of the botulinum toxin results in shrinkage of the patients prostate.
15. A method for treating prostatic hyperplasia in a human male, the method comprising the step of administering to the prostate of a patient with the prostatic hyperplasia a botulinum toxin, thereby treating the prostatic hyperplasia.
16. The method of claim 15 , wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, a powder, a cream, an emulsion, a suppository, a suspension, and a solution.
17. The method of claim 15 , wherein the botulinum toxin is administered in an injectable, pharmaceutically acceptable formulation selected from the group consisting of a liquid, a cream, an emulsion, a suspension, and a solution.
18. A method for treating benign prostatic hyperplasia in a human male, the method comprising the step of administering to the prostate of a patient with the benign prostatic hyperplasia a botulinum toxin, thereby treating the benign prostatic hyperplasia.
19. The method of claim 18 , wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, a powder, a cream, an emulsion, a suppository, a suspension, and a solution.
20. The method of claim 18 , wherein the botulinum toxin is administered in an injectable, pharmaceutically acceptable formulation selected from the group consisting of a liquid, a cream, an emulsion, a suspension, and a solution.
21. A method for treating prostate enlargement in a human male, the method comprising the step of administering to the prostate of a patient with the prostatic enlargement a botulinum toxin, thereby treating the prostatic enlargement.
22. The method of claim 21 , wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, a powder, a cream, an emulsion, a suppository, a suspension and a solution.
23. The method of claim 21 , wherein the botulinum toxin is administered in an injectable, pharmaceutically acceptable formulation selected from the group consisting of a liquid, a cream, an emulsion, a suspension, and a solution.